
    
      The study included a maximum 2-week screening period, a 4-week single-blind introduction
      period, a 24-week double-blind treatment period, a 28-week open extension treatment period,
      and a 4-week safety follow-up period.

      At the end of the single-blind entry period, eligible subjects were randomly assigned to two
      different administration groups in a 1:1 ratio and received a 24-week double-blind treatment.

      All subjects who completed the double-blind treatment entered the open extension treatment
      phase.Open extension treatment with subcutaneous injection of 150 g PB-119 once a week for 28
      weeks.

      Safety follow-up was conducted 4 weeks after the end of treatment/completion of early exit
      visit in the open extension period.
    
  